Vivani Medical
Update in progressVANI (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Vivani Medical, Inc. is a clinical‑stage biopharmaceutical company developing miniaturized subdermal drug implants to treat chronic diseases. Its NanoPortal platform enables implantable drug candidates alone or with partners. The pipeline includes NPM-139 for obesity, NPM-133 a semaglutide implant for type 2 diabetes, NPM-115 an exenatide implant for weight management, and OKV-119 for obesity and diabetes in companion animals. Based in Alameda, California.
Company score
- Sentiment
- 0.22
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.16
- Governance
- 0.07
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.06
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.14
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqCM (NCM)
- LocationUnited States
- CEODr. Adam Mendelsohn Ph.D.
- Employees42
- Websitewww.vivani.com
Identifiers
- ISINUS92854B1098
- FIGIBBG002ZQP3H7
- CUSIP92854B109
- CIK0001266806